Input your email to sign up, or if you already have an account, log in here!

I forgot my password

Enter your email address to reset your password.
A temporary password will be e‑mailed to you.

Nevermind, I remember my password

BE IN THE KNOW ON

Diabetes Herald

INDUSTRY INSIGHTS YOUR PEERS ARE READING

We organize all of the trending information in your field so you don't have to.
Join thousands of users and stay up to date on the latest articles your peers are reading.

  • About You
  • Newsletter
  • Social
  • Interests
  • Company

You know about us, now we want to get to know you!

Get us past your spam filter

Send me Diabetes Herald e-newsletter:

Check your inbox and spam folder

We have sent the latest newsletter to

Let's personalize your content

Use LinkedIn and Twitter to find articles

We can use your profile and the content you share to understand your interests and provide content that is just for you.

Turn this off at any time. Your social media activity always remains private.

Let's get even more personalized

Choose topics that interest you.

So, what do you do?

  • Biosynthetic Human Insulin (3)
  • JDRF (3)
Topics
Concepts
  • Human Insulin (3)
  • Dawn Phenomenon (1)
  • Clinical Trial (3)
  • Diabetes mellitus. (2)
  • Diabetes Mellitus (2)
  • Insulin Resistance (2)
  • Genetic (2)
  • Beta Cell (2)
  • Metabolism (3)
  • Hyperglycemia (1)
  • Basal Rate (1)
  • CDE (1)
  • Pharmacy (1)
  • Endocrinologist (1)
  • Cardiovascular (1)
  • MORE >>
Nutrition
  • Sugar (1)
Organizations
  • ADA (1)
Type
  • Comparison (2)
  • Industry (3)
  • Sample (2)
  • Project (3)
  • Process (3)
  • MORE >>
Year
  • 2001 (1)
  • 2006 (2)
  • 2008 (3)
  • 2007 (2)
  • 2009 (1)
  • MORE >>
  CHANGE EDITION
DAY WEEK MONTH YEAR
Today
Yesterday
Sun.Apr 22
Sat.Apr 21
Fri.Apr 20
Thu.Apr 19
 MORE
This Week
Last Week
Apr 07 - Apr 13
Mar 31 - Apr 06
Mar 24 - Mar 30
Mar 17 - Mar 23
 MORE
This Month
Last Month
February, 2018
January, 2018
December, 2017
November, 2017
 MORE
This Year
Last Year
2016
2015
2014
2013
 MORE
Biosynthetic Human Insulin
 + JDRF

5 articles

Page 1 of 1 Previous | Next 
SCOTT'S WEB LOG
APRIL 18, 2011
[Biosynthetic Human Insulin, JDRF] Medtronic Visit Update
Medtronic (Minimed) Diabetes is pretty much the market share leader in the insulin pump space, as the first-to-market for commercialized insulin pumps (with about 70% share of the U.S. But the insulin pump market is evolving. Growing Market for Insulin Pumps Lures New Competition, Innovation Medtronic's insulin pump competiton includes longtime rival Roche which began as a Swiss company formerly known as Disetronic back in 1984 and entered the U.S.
MORE >>
SCOTT'S WEB LOG
JUNE 2, 2010
[Biosynthetic Human Insulin, JDRF] Scott's Web Log: The Business of Diabetes: Is Novo Nordisk's.
First, Novo Nordisk is not, as some have mistakenly claimed, leaving any Greek type 1 patients to die without access to Novo Nordisk insulin. There is some concern that other insulin manufacturers, notably Eli Lilly & Co.
MORE >>
RECENT POSTS
APRIL 18, 2011  |  SCOTT'S WEB LOG
[Biosynthetic Human Insulin, JDRF] Medtronic Visit Update
JUNE 2, 2010  |  SCOTT'S WEB LOG
[Biosynthetic Human Insulin, JDRF] Scott's Web Log: The Business of Diabetes: Is Novo Nordisk's.
JULY 9, 2009  |  SCOTT'S WEB LOG
[Biosynthetic Human Insulin, JDRF] Scott's Web Log: Evergreening Does Not Refer to Trees
JULY 14, 2008  |  SCOTT'S WEB LOG
[Biosynthetic Human Insulin, JDRF] New Research Clarifies Distinction Between Different Types of Diabetes
JULY 14, 2008  |  SCOTT'S WEB LOG
[Biosynthetic Human Insulin, JDRF] New Research Clarifies Distinction Between Different Types of Diabetes
MORE >>
SCOTT'S WEB LOG
JULY 14, 2008
[Biosynthetic Human Insulin, JDRF] New Research Clarifies Distinction Between Different Types of Diabetes
Some authors even argued that type 1 and type 2 diabetes are actually the same disorder of insulin resistance, set against different genetic backgrounds (unfortunately for them, their so-called " Accelerator Hypothesis " had numerous shortcomings, particularly the fact that relatively few of the children in their own research sample were overweight, the insulin requirements of lean patients were statistically much lower than those who were overweight, as well as many other shortcomings).
MORE >>
SCOTT'S WEB LOG
JULY 14, 2008
[Biosynthetic Human Insulin, JDRF] New Research Clarifies Distinction Between Different Types of Diabetes
Some authors even argued that type 1 and type 2 diabetes are actually the same disorder of insulin resistance, set against different genetic backgrounds (unfortunately for them, their so-called " Accelerator Hypothesis " had numerous shortcomings, particularly the fact that relatively few of the children in their own research sample were overweight, the insulin requirements of lean patients were statistically much lower than those who were overweight, as well as many other shortcomings).
MORE >>
SCOTT'S WEB LOG
JULY 9, 2009
[Biosynthetic Human Insulin, JDRF] Scott's Web Log: Evergreening Does Not Refer to Trees
Some also say the effective extension of patents on biosynthetic human insulin is also an example of evergreening. This would mean that no pharmacy could simply give us a "generic" insulin without asking our permission as they can with pills.
MORE >>
 
Sign In Join thousands of INSIDERS Sign Up for our Newsletter
Featured
  • Beta Buddies
  • Insulin Nation
  • Justice's Misbehaving Pancreas
  • Luke's Day
  • My New Islets
  • Our Diabetic Life
  • Type 1 Skill Set

Recent Editions
  • Yesterday
  • Sun.Apr 22
  • Sat.Apr 21
  • Fri.Apr 20
  • Last Week
  • Thu.Apr 19
  • Wed.Apr 18
  • Tue.Apr 17
  • MORE >>

Pages
  • Learn More
  • Participate in Diabetes Herald

www.aggregage.com | Terms and Conditions and Privacy Policy | Get a widget
© Aggregage 2018